Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Rossi

Showing results (31-40 of 516) with videos related to

Pageof 52
Sort By:
Journal of Thoracic Disease|April 19, 2019
Prophylactic cranial irradiation in non-small cell lung cancer: the debate is openCarlo Greco, Antonio Rossi, Sara Ramella
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly?Cesare Gridelli, Paolo Maione, Antonio Rossi
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2011
Switch maintenance versus second-line treatment in non-small cell lung cancerAntonio Rossi, Valter Torri, Cesare Gridelli
Oncology|February 5, 2010
Biological prognostic and predictive factors in lung cancerAntonio Rossi, Domenico Galetta, Cesare Gridelli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug?Cesare Gridelli, Paolo Maione, Antonio Rossi
Reviews on Recent Clinical Trials|December 25, 2012
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancerCesare Gridelli, Paolo Maione, Antonio Rossi
The New England Journal of Medicine|April 16, 2008
Paclitaxel plus bevacizumab for metastatic breast cancerAntonio Rossi, Valter Torri, Cesare Gridelli
Critical Reviews in Oncology/Hematology|April 22, 2008
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancerCesare Gridelli, Antonio Rossi, Paolo Maione
Translational Lung Cancer Research|November 6, 2018
Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapyUmberto Malapelle, Antonino Iaccarino, Antonio Rossi
Oncogene|October 7, 2003
Treatment of non-small-cell lung cancer: state of the art and development of new biologic agentsCesare Gridelli, Antonio Rossi, Paolo Maione
Pageof 52

Showing results (31-40 of 516) with videos related to

Sort By:
Pageof 52
Journal of Thoracic Disease|April 19, 2019
Prophylactic cranial irradiation in non-small cell lung cancer: the debate is openCarlo Greco, Antonio Rossi, Sara Ramella
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly?Cesare Gridelli, Paolo Maione, Antonio Rossi
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2011
Switch maintenance versus second-line treatment in non-small cell lung cancerAntonio Rossi, Valter Torri, Cesare Gridelli
Oncology|February 5, 2010
Biological prognostic and predictive factors in lung cancerAntonio Rossi, Domenico Galetta, Cesare Gridelli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Single-agent chemotherapy for the treatment of elderly patients with advanced non-small-cell lung cancer: what is the best drug?Cesare Gridelli, Paolo Maione, Antonio Rossi
Reviews on Recent Clinical Trials|December 25, 2012
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancerCesare Gridelli, Paolo Maione, Antonio Rossi
The New England Journal of Medicine|April 16, 2008
Paclitaxel plus bevacizumab for metastatic breast cancerAntonio Rossi, Valter Torri, Cesare Gridelli
Critical Reviews in Oncology/Hematology|April 22, 2008
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancerCesare Gridelli, Antonio Rossi, Paolo Maione
Translational Lung Cancer Research|November 6, 2018
Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapyUmberto Malapelle, Antonino Iaccarino, Antonio Rossi
Oncogene|October 7, 2003
Treatment of non-small-cell lung cancer: state of the art and development of new biologic agentsCesare Gridelli, Antonio Rossi, Paolo Maione
Pageof 52